论文部分内容阅读
目的 将经肝动脉化疗栓塞 (TACE)和经门静脉植入化疗药盒持续灌注化疗药 (VPC) 2种方法结合 ,观察原发性肝癌(HCC)经肝动脉化疗栓塞和经门静脉植入化疗药盒持续灌注化疗药的疗效。方法 对照组 83例中晚期患者 ,用表柔比星 (EPI) 40mg和顺铂 (CDDP) 80mg与碘化油配制成碘油———化疗药物乳化剂 ,经导管向肝癌供血动脉注入 ,后用明胶海绵 (GS)颗粒栓塞该动脉。治疗组 5 9例中晚期HCC患者 ,用上述方法治疗后 ,再经皮下埋置式药盒经门静脉定期灌注化疗药。结果 对照组与治疗组有效率 (完全缓解 +部分缓解 )分别为 45 .8%和 61.0 % (P <0 .0 5 ) ,2组治疗后Ⅱ期手术切除率分别为 3 .6%和 11.9% (P <0 .0 5 )。对照组 1年、2年、3年生存率分别为 69.9%、60 .2 %和 2 0 .5 % ;治疗组分别为 96.6%、67.8%和 42 .4% (P <0 .0 5 )。并发症差异无显著性意义。结论 经肝动脉化疗栓塞和经门静脉植入化疗药盒持续灌注化疗药是治疗原发性肝癌的较好方法 ,能提高疗效
Objective To evaluate the efficacy of transcatheter hepatic arterial chemoembolization (TACE) combined with chemotherapeutic drug (VPC) via portal vein chemotherapy (VPC) Continuous infusion of chemotherapeutic drugs. Methods Eighty-three patients in the control group were treated with EPO 40mg and CDDP 80mg and iodized oil to prepare iodized oil-chemotherapy drug emulsifier. The artery was embolized with gelatin sponge (GS) particles. In the treatment group, 59 patients with advanced and middle stage HCC were treated with the above-mentioned methods, and then the chemotherapy drugs were infused through the portal vein through the subcutaneous embedded kit. Results The effective rate (complete remission + partial remission) in the control group and the treatment group were 45.8% and 61.0% (P 0.05). The surgical resection rates of the two groups after treatment were respectively 3.6% and 11.9% % (P <0 .0 5). The 1-year, 2-year and 3-year survival rates of the control group were 69.9%, 60.2% and 20.5% respectively; the treatment group was 96.6%, 67.8% and 42.4%, respectively (P0.05) . No significant difference in complications. Conclusions Continuous chemoembolization via transcatheter arterial chemoembolization and chemotherapy via the portal vein is a good way to treat primary hepatocellular carcinoma and can improve the curative effect